Provention Bio Stock Soars on $2.9 Billion Acquisition by Sanofi

Shares of Provention Bio soared Monday after the biopharmaceutical company agreed to be acquired by France’s Sanofi (SNY) for $25 a share, or about $2.9 billion. Provention Bio (ticker: PRVB), which f...

First Republic, Provention Bio, Roku, Illumina, Boeing, and More Market Movers

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barro...

Opinion: The stock market is telling you loud and clear: Now is not the time to fight the Fed or stand up to the bears.

The S&P 500 Index SPX, -1.85% hit resistance this week when an oversold rally failed near the 4080 level. This continues to support the idea that the index’s rise above 4100 in early February was ...

BridgeBio Stock Surges on Dwarfism Drug Data. It’s Bad News for BioMarin.

BridgeBio Pharma stock was soaring after the biopharmaceutical company reported positive results in a Phase two clinical trial for an experimental treatment for achondroplasia, the most common type of...

The 20 worst U.S. stocks in February: the biggest loser dropped 35%

Updated with month-end prices. The euphoria of January reversed in February, with broad declines for stocks across the board as interest rates continued to rise. Bond interest rates are more attractiv...

This is what Warren Buffett, a self-described ‘so-so investor,’ says is his ‘secret sauce’

Stocks are rebounding on the heels of a rotten week — the worst since December for the S&P 500 SPX, +1.15% and the Nasdaq Composite COMP, +1.39%. And as Wall Street analysts go dark, with talk of ...

U.S. Clean Energy Is Attracting Billions. Corning, Enphase, and Other Key Players.

A boom in clean-energy manufacturing is fast getting under way across the U.S. Factories are suddenly cranking out everything from solar and wind equipment to batteries and low-carbon fuel. Corporate ...

Boeing stock slips after deliveries of 787s halted; Beyond Meat shares rally after plant-food maker’s results

Here are some of the most active stocks in premarket trade. U.S. stock futures were pointing to a lower start ahead of the release of inflation data. Boeing stock BA, -4.07% fell 3% as the airplane ma...

Crispr Therapeutics: FDA Filing on Sickle Cell Gene Therapy Is Almost Done

An approval filing for a breakthrough treatment of sickle cell disease should be done by March, Crispr Therapeutics said, highlighting the company’s lead in a competitive area of medical research and ...

Here are five companies to pick if Goldman Sachs is right about the stock market being flat in 2023

Hearts, flowers and CPI data. Get ready for Tuesday. And hell hath no fury like a disappointed Wall Street. The last time CPI let the markets down — last September — stocks melted down like chocolate....

JNJ Bought Up Biotech Stock MeiraGTx. It Sold Procept BioRobotics.

Johnson & Johnson recently increased an investment in an embattled biotech stock, and slashed a position in a maker of surgical robotics that rocketed last year. Johnson & Johnson (ticker: JNJ...

Gambling on Biotechs—and Pfizer | Barron’s

To the Editor: Pfizer has a lot of good and bad points, as mentioned in your cover story “Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy.” (Feb. 3). But the hardest one to deal with for all bio...

Enphase stock rallies 8% after Q4 earnings blow past expectations, guidance

Enphase Energy Inc. shares jumped more than 8% in the extended session Tuesday after the maker of inverters for solar-power systems reported fourth-quarter earnings that topped Wall Street views and u...

Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy.

Pfizer probably did more than any other company to help the world normalize from the pandemic, and it reaped a financial windfall from its twin Covid-19 franchise—the top-selling vaccine and the leadi...

What investors need to know about Pfizer’s latest downgrade

Pfizer’s PFE, -0.92% early-stage pipeline, though promising, is still too premature to make up for the looming loss of billions of dollars from the company’s COVID-19 franchise, which includes the vac...

CureVac Stock Just Got Upgraded. It’s Now a Competitor in mRNA Vaccines.

CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise. UBS analyst Eliana Merle upgraded the shares (ticker: CVA...

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%. The other most-watched exchange-traded fund that tracks the biotech sector, the...

Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.

Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...